Search Results - "Cavina, R"

Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer by Franzese, Ciro, Badalamenti, M., Teriaca, A., De Virgilio, A., Mercante, G., Cavina, R., Ferrari, D., Santoro, A., Spriano, G., Scorsetti, M.

“…Introduction Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We…”
Get full text

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients by Cappuzzo, F., Tallini, G., Finocchiaro, G., Wilson, R.S., Ligorio, C., Giordano, L., Toschi, L., Incarbone, M., Cavina, R., Terracciano, L., Roncalli, M., Alloisio, M., Varella-Garcia, M., Franklin, W.A., Santoro, A.

“…The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected…”
Get full text

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer by PARRA, H. S, CAVINA, R, LATTERI, F, ZUCALI, P. A, CAMPAGNOLI, E, MORENGHI, E, GRIMALDI, G. C, RONCALLI, M, SANTORO, A

“…Gefitinib ('Iressa', ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity…”
Get full text

Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma: Feasibility and tolerability in elderly and chemotherapy-ineligible patients by Alongi, F., Bignardi, M., Garassino, I., Pentimalli, S., Cavina, R., Mancosu, P., Reggiori, G., Poletti, A., Ferrari, D., Foa, P., Bigoni, A., Dragonetti, A., Salvatori, P., Spahiu, O., Fogliata, A., Cozzi, L., Santoro, A., Scorsetti, M.

“…Introduction Cetuximab plus radiotherapy (RT) may be an effective alternative to chemoradiation in locally advanced head and neck squamous cell carcinoma…”
Get full text

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer by Licitra, L., Locati, L. D., Cavina, R., Garassino, I., Mattavelli, F., Pizzi, N., Quattrone, P., Valagussa, P., Gianni, L., Bonadonna, G., Solero, C. L., Cantu, G.

“…Background: To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer…”
Get full text

Unresectable Locally Advanced Non-small Cell Lung Cancer: Early Clinical Experience for Large Volume Targets using Volumetric Modulated Arc Therapy by Scorsetti, M, Navarria, P, Mancosu, P, Castiglioni, S, Bressi, C, Fogliata, A, Clerici, E, Cavina, R, Santoro, A, Cozzi, L

Get full text

9103 POSTER Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC) by Viganò, M, Cavina, R, Novello, S, Grossi, F, Santoro, A, Gregore, V, Rossoni, G, Levra, M.G, Lambiase, A, Bordignon, C

Get full text

870 poster SIMULTANEOUS INTEGRATED BOOST WITH VOLUMETRIC INTENSITY MODULATED RADIOTHERAPY(RAPID ARC) IN THE RADICAL TREATMENT OF 51 ADVANCED HEAD AND NECK CANCER PATIENTS: A PRELIMINARY REPORT by Alongi, F, Pentimalli, S, Clerici, E, Mancosu, P, Cozzi, L, Cavina, R, Fogliata, A, Castiglioni, S, Tozzi, A, Navarria, P, Chiti, A, Santoro, A, Scorsetti, M

Get full text

SIMULTANEOUS INTEGRATED BOOST WITH VOLUMETRIC INTENSITY MODULATED RADIOTHERAPY (RAPID ARC) IN THE RADICAL TREATMENT OF 47 ADVANCED HEAD AND NECK CANCER PATIENTS: A PRELIMINARY REPORT by Alongi, F, Pentimalli, S, Clerici, E, Mancosu, P, Cavina, R, Bignardi, M, Castiglioni, S, Tozzi, A, Navarria, P, Santoro, A, Scorsetti, M

Get full text

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients by Licitra, L, Cavina, R, Grandi, C, Palma, S D, Guzzo, M, Demicheli, R, Molinari, R

“…To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Twenty-two patients with advanced salivary gland carcinomas were treated…”
Get full text

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study by Soto Parra, H., Cavina, R., Latteri, F., Sala, A., Dambrosio, M., Antonelli, G., Morenghi, E., Alloisio, M., Ravasi, G., Santoro, A.

“…Background: The cisplatin and gemcitabine (GC) regimen is usually administered as a 4- or 3-week schedule; however, the best schedule to use is still unclear…”
Get full text

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial by Cardinale, Daniela, Latini, Roberto, Franzosi, Maria Grazia, Civelli, Maurizio, Cucchi, GianFranco, Menatti, Elisabetta, Mangiavacchi, Maurizio, Cavina, Raffaele, Gori, Stefania, Colombo, Alessandro, Curigliano, Giuseppe, Salvatici, Michela, Rizzo, Antonio, Ghisoni, Francesco, Bianchi, Alessandra, Falci, Cristina, Rocca, Andrea, Monopoli, Anna, Milandri, Carlo, Bregni, Marco, Sicuro, Marco, Giordano, Monica, Staszewsky, Lidia, Nicolis, Enrico B., Masson, Serge, Cipolla, Carlo M., Cipolla, C.M., Cardinale, D., Ciceri, F., Latini, R., Sandri, M.T., Maggioni, A.P., Labianca, R., Finzi, A., Vago, T., Civelli, M., Gramenzi, S., Masson, S., Balconi, G., Bernasconi, R., Salvatici, M., Nicolis, E., Magnoli, M., Buratti, M.G., Malossi, A., Sicuro, M., Thiebat, B., Corzani, A., Colecchia, S., Pellegrini, C., Bregni, M., Appio, L., Caico, I., G.Rossetti, Mesenzani, O., Campana, C., Giordano, M., Gilardoni, M., Scognamiglio, G., Corrado, G., Battagin, D., Monopoli, A., Giannessi, P.G., Zipoli, G., Ghisoni, F., Rizzo, A., Callegari, S., Sesenna, C., Colombo, A., G.Curigliano, Fodor, C., Cavina, R., Mazza, R., Vallerio, P., Marbello, L., Sala, E., Fragasso, G., Trinca, S., Rocca, A., Farolfi, A., Gori, S., Barbieri, E., Lanzoni, L., Falci, C., Bianchi, A., Mioranza, E., Re, F., Gaibazzi, N., Turina, M.C., Giaroli, F., Nassiacos, D., Verusio, C., Barco, B., Bertolini, A., Menatti, E., Sinagra, G., Aleksova, A., Pinotti, G., Gueli, R., Mongiardi, C.

“…Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin…”
Get full text

9084 Pemetrexed vs docetaxel as second-line in NSCLC: is there a difference between adenocarcinoma and squamous cell carcinoma? – a retrospective analysis of a single institution by Garassino, I, Cavina, R, Gandini, C, Cappuzzo, F, Giordano, L, Rahal, D, Roncalli, M, Santoro, A

Get full text

Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose by Cerrotta, A, Gardan, G, Cavina, R, Raspagliesi, F, Stefanon, B, Garassino, I, Musumeci, R, Tana, S, De Palo, G

“…This study included patients with inoperable primary or recurrent cervical cancer whose treatment plan called for exclusive radiotherapy. The endopoints of the…”
Get more information

Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer by Santoro, A., Cavina, R., Latteri, F., Zucali, P. A., Ginanni, V., Campagnoli, E., Ferrari, B., Morenghi, E., Pedicini, V., Roncalli, M., Alloisio, M., Ravasi, G., Soto Parra, H. J.

“…Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies…”
Get full text

Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma : A phase II trial by LICITRA, L, CAPRI, G, FULFARO, F, GRANDI, C, TARENZI, E, CAVINA, R, GIANNI, L

“…Cisplatin is an active drug in head and neck cancer. Paclitaxel seems a promising drug. This article reports a phase II assessment of the combination of the…”
Get full text

Cross regimen for oesophageal cancer: Single center experience by Puccetti, F., De Pascale, S., Garassino, I., Cavina, R., Tozzi, A., Fumagalli, U., Rosati, R.

Get full text

CROSS regimen for Oesophageal Cancer: single center experience by Garassino, I.M.G., de Pascale, S., Puccetti, F., Cavina, R., Tozzi, A., Santoro, A., Fumagalli Romario, U.

Get full text

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma by CERESOLI, Giovanni L, ZUCALI, Paolo A, MARANGOLO, Maurizio, SOTO PARRA, Hector J, SANTORO, Armando, FAVARETTO, Adolfo G, GROSSI, Francesco, BIDOLI, Paolo, DEL CONTE, Guido, CERIBELLI, Anna, BEARZ, Alessandra, MORENGHI, Emanuela, CAVINA, Raffaele

“…This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant…”
Get full text

ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND by Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M.C., De Sanctis, R.M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., Santoro, A.

Get full text